BriaCell Therapeutics Corp. (BCT.TO)
CAD 0.87
(-4.4%)
CAD 0.87
(-4.4%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 | 5.87 Million USD | -78.38% |
| 2023 | 27.16 Million USD | -36.2% |
| 2022 | 42.57 Million USD | -26.65% |
| 2021 | 58.04 Million USD | 12035.15% |
| 2020 | 478.31 Thousand CAD | 15.14% |
| 2019 | 415.43 Thousand CAD | -81.82% |
| 2018 | 2.28 Million CAD | 39.66% |
| 2017 | 1.63 Million CAD | 95.78% |
| 2016 | 835.69 Thousand CAD | -34.52% |
| 2015 | 1.27 Million CAD | -50.7% |
| 2014 | 2.58 Million CAD | -72.48% |
| 2013 | 9.4 Million CAD | -8.82% |
| 2012 | 10.31 Million CAD | -16.41% |
| 2011 | 12.34 Million CAD | 738.57% |
| 2010 | 1.47 Million CAD | 41.73% |
| 2009 | 1.03 Million CAD | 172.75% |
| 2008 | 380.81 Thousand CAD | -16.54% |
| 2007 | 456.29 Thousand CAD | 373.56% |
| 2006 | 96.35 Thousand CAD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 12.23 Million USD | -34.31% |
| 2024 Q1 | 18.61 Million USD | -31.46% |
| 2024 Q3 | 6.2 Million USD | -49.28% |
| 2024 Q4 | 5.87 Million USD | -5.34% |
| 2023 Q4 | 27.16 Million USD | -8.61% |
| 2023 Q3 | 29.72 Million USD | -13.0% |
| 2023 Q2 | 34.16 Million USD | -11.15% |
| 2023 Q1 | 38.45 Million USD | -9.69% |
| 2023 FY | 27.16 Million USD | -36.2% |
| 2022 Q3 | 46.46 Million USD | -4.31% |
| 2022 Q2 | 48.55 Million USD | -13.54% |
| 2022 Q1 | 56.15 Million USD | -3.25% |
| 2022 FY | 42.57 Million USD | -26.65% |
| 2022 Q4 | 42.57 Million USD | -8.36% |
| 2021 Q2 | 457.46 Thousand CAD | 1.01% |
| 2021 FY | 58.04 Million USD | 12035.15% |
| 2021 Q1 | 452.89 Thousand CAD | -5.31% |
| 2021 Q4 | 58.04 Million USD | 175.76% |
| 2021 Q3 | 21.04 Million CAD | 4501.18% |
| 2020 Q2 | 478.13 Thousand CAD | 0.36% |
| 2020 Q4 | 478.31 Thousand CAD | 8.76% |
| 2020 FY | 478.31 Thousand CAD | 15.14% |
| 2020 Q1 | 476.43 Thousand CAD | 14.68% |
| 2020 Q3 | 439.79 Thousand CAD | -8.02% |
| 2019 Q3 | 1.19 Million CAD | 27.85% |
| 2019 Q1 | 1.4 Million CAD | -38.44% |
| 2019 FY | 415.43 Thousand CAD | -81.82% |
| 2019 Q4 | 415.43 Thousand CAD | -65.35% |
| 2019 Q2 | 937.72 Thousand CAD | -33.33% |
| 2018 Q3 | 3.7 Million CAD | 365.43% |
| 2018 FY | 2.28 Million CAD | 39.66% |
| 2018 Q4 | 2.28 Million CAD | -38.39% |
| 2018 Q2 | 796.89 Thousand CAD | -39.48% |
| 2018 Q1 | 1.31 Million CAD | -19.53% |
| 2017 Q1 | 1.64 Million CAD | 97.01% |
| 2017 Q4 | 1.63 Million CAD | 2.85% |
| 2017 FY | 1.63 Million CAD | 95.78% |
| 2017 Q3 | 1.59 Million CAD | 16.2% |
| 2017 Q2 | 1.36 Million CAD | -16.85% |
| 2016 Q4 | 835.69 Thousand CAD | -31.12% |
| 2016 Q1 | 978.46 Thousand CAD | -23.33% |
| 2016 Q3 | 1.21 Million CAD | 101.25% |
| 2016 Q2 | 602.87 Thousand CAD | -38.39% |
| 2016 FY | 835.69 Thousand CAD | -34.52% |
| 2015 Q2 | 1.76 Million CAD | -34.38% |
| 2015 FY | 1.27 Million CAD | -50.7% |
| 2015 Q3 | 1.66 Million CAD | -5.68% |
| 2015 Q4 | 1.27 Million CAD | -23.48% |
| 2015 Q1 | 2.69 Million CAD | 4.09% |
| 2014 FY | 2.58 Million CAD | -72.48% |
| 2014 Q4 | 2.58 Million CAD | -68.28% |
| 2014 Q3 | 8.16 Million CAD | -4.55% |
| 2014 Q2 | 8.55 Million CAD | -6.8% |
| 2014 Q1 | 9.17 Million CAD | -2.48% |
| 2013 Q3 | 9.65 Million CAD | -2.12% |
| 2013 Q2 | 9.86 Million CAD | -2.06% |
| 2013 Q1 | 10.07 Million CAD | -2.39% |
| 2013 FY | 9.4 Million CAD | -8.82% |
| 2013 Q4 | 9.4 Million CAD | -2.56% |
| 2012 Q4 | 10.31 Million CAD | -4.77% |
| 2012 Q3 | 10.83 Million CAD | -1.2% |
| 2012 Q2 | 10.96 Million CAD | -3.57% |
| 2012 Q1 | 11.37 Million CAD | -7.87% |
| 2012 FY | 10.31 Million CAD | -16.41% |
| 2011 Q1 | 1.47 Million CAD | 0.14% |
| 2011 Q2 | 1.31 Million CAD | -10.9% |
| 2011 Q3 | 12.16 Million CAD | 825.74% |
| 2011 Q4 | 12.34 Million CAD | 1.51% |
| 2011 FY | 12.34 Million CAD | 738.57% |
| 2010 Q1 | 942.59 Thousand CAD | -9.25% |
| 2010 Q3 | 1.87 Million CAD | 111.1% |
| 2010 Q2 | 886.04 Thousand CAD | -6.0% |
| 2010 FY | 1.47 Million CAD | 41.73% |
| 2010 Q4 | 1.47 Million CAD | -21.29% |
| 2009 Q3 | 452.75 Thousand CAD | 92.84% |
| 2009 Q4 | 1.03 Million CAD | 129.41% |
| 2009 Q2 | 234.78 Thousand CAD | -12.12% |
| 2009 Q1 | 267.15 Thousand CAD | -29.85% |
| 2009 FY | 1.03 Million CAD | 172.75% |
| 2008 FY | 380.81 Thousand CAD | -16.54% |
| 2008 Q4 | 380.81 Thousand CAD | -11.34% |
| 2008 Q3 | 429.53 Thousand CAD | -6.2% |
| 2008 Q2 | 457.93 Thousand CAD | -10.09% |
| 2008 Q1 | 509.32 Thousand CAD | 11.62% |
| 2007 Q4 | 456.29 Thousand CAD | -1.53% |
| 2007 Q2 | 441.9 Thousand CAD | -8.08% |
| 2007 Q3 | 463.36 Thousand CAD | 4.86% |
| 2007 Q1 | 480.75 Thousand CAD | 0.0% |
| 2007 FY | 456.29 Thousand CAD | 373.56% |
| 2006 FY | 96.35 Thousand CAD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Appili Therapeutics Inc. | 1.49 Million CAD | -294.005% |
| Eupraxia Pharmaceuticals Inc. | 26.72 Million CAD | 78.025% |
| Helix BioPharma Corp. | 1.48 Million CAD | -294.376% |
| Microbix Biosystems Inc. | 35.65 Million CAD | 83.529% |
| Medicenna Therapeutics Corp. | 19.13 Million CAD | 69.31% |
| Satellos Bioscience Inc. | 44.29 Million CAD | 86.744% |
| Oncolytics Biotech Inc. | 38.82 Million CAD | 84.873% |
| Sernova Corp. | 22.1 Million CAD | 73.437% |